DNX-2465

DNX-2465 is an investigational oncolytic virus therapy being developed by DNAtrix for the treatment of solid tumors. As part of the DNAtrix pipeline, it likely utilizes the company's proprietary Delta-24 platform, which involves a conditionally replicative adenovirus engineered to selectively infect and lyse cancer cells while sparing normal tissue. The therapy is designed to induce direct oncolysis and stimulate a systemic anti-tumor immune response by releasing tumor-associated antigens into the microenvironment. While specific details regarding its genetic payload or modifications are limited in public disclosures, it represents an expansion of the company's oncolytic adenovirus technology beyond its lead glioblastoma assets.